A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
for Endometrial Cancer
44 locations incl. Mobile
Sponsor: Merck Sharp & Dohme LLC
Sex: Female·Age: 18+
Code: NCT06952504·Phase 3·Recruiting